A clinical-stage biopharma company focused on the development of novel therapeutics for the treatment of rare diseases.
Location: United States
Employees: 51-200
Total raised: $264.5M
Founded date: 2014
Investors 8
Funding Rounds 4
| Date | Series | Amount | Investors |
| 03.08.2023 | - | $115M | Hercules C... |
| 02.10.2020 | - | $85M | - |
| 16.11.2017 | Series B | $27M | - |
| 14.12.2015 | Series A | $37.5M | - |
Mentions in press and media 22
| Date | Title | Description |
| 17.04.2025 | Norgine strengthens rare disease portfolio with acquisition of Theravia | Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's posit... |
| 25.01.2025 | X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe. | LONDON, Jan. 25, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment... |
| 12.03.2024 | X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024 | - |
| 07.03.2024 | Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program | Net operating losses converted into non-dilutive capital CRANFORD, N.J., March 7, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedic... |
| 30.01.2024 | COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures | - |
| 03.08.2023 | X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital | - |
| 03.08.2023 | X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital | - |
| 26.09.2022 | DAMONA Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging | TORONTO, Ontario, September 26, 2022 — DAMONA Pharmaceuticals today announced the closing of a seed stage financing round to support the development of its lead therapeutic for the treatment of cognitive symptoms associated with depression ... |
| 26.07.2022 | X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months | X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4 targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it has agreed to sell an aggreg... |
| 20.01.2022 | China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment | TAIZHOU, China, Jan. 20, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, market... |
Show more